Due to health issues, this site is no longer maintained and will be shut down shortly. |
MorphoSys AG engages in the development of therapeutic antibodies to cure inflammatory and autoimmune diseases, as well as cancer and infectious diseases. The company operates through two business segments; Partnered Discovery and Proprietary Development. This is an ADR of a company whose stock trades outside of the U.S. as the symbol GF:MOR.
$3.99 +0.05 (1.27%)
As of 03/27/2023 11:30:07 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.